OTC
ESPR

Opera Trading Capital’s Esperion Therapeutics ESPR Stock Holding History

Opera Trading Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,896
Closed -$173K – 111
2018
Q3 		$173K Buy
+3,896
New +$179K 0.03% 121

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Opera Trading Capital's ESPR Position: Q4 2018 in Review

Opera Trading Capital sold out of Esperion Therapeutics (ESPR) in Q4 2018, closing a stake of 3,896 shares — an estimated $173K sold.

Opera Trading Capital first reported a position in ESPR in Q3 2018 and held it in 1 quarter. The position peaked at $173K in Q3 2018. 156 funds tracked by Wall St. Rank hold ESPR as of Q4 2018.

  • Opera Trading Capital reported no remaining Esperion Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Opera Trading Capital sold 3,896 Esperion Therapeutics shares in Q4 2018, an estimated $173K.
  • Opera Trading Capital first reported a position in Esperion Therapeutics in Q3 2018 and held it in 1 quarter.
  • Opera Trading Capital's Esperion Therapeutics position peaked at $173K in Q3 2018.
  • 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2018.

Based on Opera Trading Capital's 13F filing for Q4 2018, filed 22 Jan 2019.